Organicell Regenerative Medicine has reported positive results from the trial of its acellular biologic therapeutic Zofin for treating patients with moderate to severe Covid-19 in India.

Data showed that the first ten subjects who received Zofin recovered from Covid-19 symptoms and were discharged from hospital.

Zofin is obtained from perinatal sources. It is manufactured to preserve naturally occurring microRNAs, without adding any other substance or diluent.

The therapeutic contains over 300 growth factors, cytokines, and chemokines, along with other extracellular vesicles/nanoparticles obtained from perinatal tissues.

This initial trial is being carried out in collaboration with Organicell’s partner, CWI India.

In February this year, the companies signed a product testing and distribution agreement to analyse the effects of Zofin on moderate to severe Covid-19 patients.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Organicell Regenerative Medicine CEO Albert Mitrani said: “The explosive spread of Covid-19 in India, and the lack of treatment that is available to help these millions of people is quite alarming and tragic.

“We are hopeful that Zofin can continue to help these patients, and we will do everything we can to expedite this process.

The trial will be expanded to include 65 subjects with moderate to severe Covid-19. They will receive treatment at various hospitals in India for the next several weeks, with completion expected by the end of June.

On obtaining positive results of the expanded trial, Organicell and CWI India plan to submit an application to the Indian Council for Medical Research seeking emergency use approval for using Zofin as a Covid-19 therapeutic.

Doctor Matthew Roshan of CWI India said: “We are very encouraged with the results shown by patients using Zofin and are hopeful that the remaining trial patients will show similar results.

“These trials could set the stage for a very quick emergency use approval to be able to use Zofin for all of our patients.”

Last week, Organicell concluded patient enrolment for its expanded access trial of Zofin to treat Covid-19.